For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The Global Pharma and Biotech M&A Trends 2010-2015 report provides comprehensive understanding and unprecedented access to the merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all merger and acquisition deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of M&A dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an analysis of the trends in M&A as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of M&A deals. The chapter includes numerous case studies to enable understanding of M&A deals.
Chapter 4 provides a review of the leading M&A deals since 2010. Deals are listed by headline value, signed by bigpharma and and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 big pharma companies (with M&A announements) with a brief summary followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of the top 50 big biotech companies (with M&A announements) with a brief summary followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of M&A deals signed and announced since 2010 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the M&A deal.
In addition the report includes a comprehensive listing of all M&A deals announced since 2010. Each listing is organized as an appendix by company A-Z, and industry sector. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in M&A dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about M&A alliances.
Global Pharma and Biotech M&A Trends 2010-2015 report provides the reader with the following key benefits:
- In-depth understanding of M&A deal trends since 2010
- Analysis of the structure of M&A agreements with numerous real life case studies
- Comprehensive access to over 2,500 actual M&A deals entered into by the world's biopharma companies, together with contract documents if available
- Detailed access to actual M&A deals entered into by the leading fifty big pharma and big biotech companies
- Insight into the terms included in a M&A agreement, together with real world clause examples
- Full listing of M&A deals by company A-Z and industry sector
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies